DBV Technologies has filed a prospectus with the U.S. SEC to renew its At-The-Market (ATM) offering program, allowing it to raise up to $150 million by selling American Depositary Shares (ADSs). The funds will primarily support expanding manufacturing capacity, pursuing product license applications for children aged 1 to 7, preparing the launch of VIASKIN® Peanut, and advancing other product candidates. The program continues under existing terms with Citizens JMP Securities as the placement agent. This financing move supports DBV's ongoing development of immunotherapy treatments for food allergies using its VIASKIN® platform.
Regions Financial Corporation's stock surged to a 52-week high of $32.47 following a Jefferies analyst upgrade raising the price target to $32. The bank reported strong Q2 2026 adjusted earnings of $0.68 per share, beating estimates of $0.64, driven ...
Several key stocks fell significantly due to company-specific issues. Intuitive Surgical's shares dropped 14.15% despite strong earnings because of slower growth in surgical procedures, impacting related leveraged ETFs. REGENXBIO's stock fell 11.7% a...
Glencore has amended and restated its $5 million convertible loan agreement with Tantalex Lithium Resources Corporation, splitting the loan into three facilities with adjusted terms and interest rates. The amended agreement includes a 1% gross revenu...
A Race Against Blindness, an Arizona nonprofit, has launched its first electric vehicle fundraiser featuring a 2025 Volkswagen ID. Buzz and $20,000 cash as the grand prize. Running from July 13 to 26, the campaign aims to raise funds for clinical tri...
HSBC has upgraded Meta Platforms to a Buy rating, reflecting confidence in its new cloud computing strategy. Meta is negotiating a potential $10 billion deal to lease its computing infrastructure to AI research lab Anthropic, addressing the global ha...
